[1] |
Kawecki D, Chmura A, Pacholczyk M, et al. Bacterial infections in the early period after liver transplantation: etiological agents and their susceptibility [J]. Med Sci Monit, 2009, 15(12): CR628-CR637.
|
[2] |
Sullivan T, Weinberg A, Rana M, et al. The epidemiology and clinical features of clostridium difficile infection in liver transplant recipients [J]. Transplantation, 2016, 100(9): 1939-1943. DOI: 10.1097/TP.0000000000001309.
|
[3] |
Kim SI, Kim YJ, Jun YH, et al. Epidemiology and risk factors for bacteremia in 144 consecutive living-donor liver transplant recipients [J]. Yonsei Med J, 2009, 50(1): 112-121. DOI: 10.3349/ymj.2009.50.1.112.
|
[4] |
Iida T, Kaido T, Yagi S, et al. Posttransplant bacteremia in adult living donor liver transplant recipients [J]. Liver Transpl, 2010, 16(12): 1379-1385. DOI: 10.1002/lt.22165.
|
[5] |
Siniscalchi A, Aurini L, Benini B, et al. Ventilator associated pneumonia following liver transplantation: etiology, risk factors and outcome [J]. World J Transplant, 2016, 6(2): 389-395. DOI: 10.5500/wjt.v6.i2.389.
|
[6] |
Smith CT, Katz MG, Foley D, et al. Incidence and risk factors of incisional hernia formation following abdominal organ transplantation [J]. Surg Endosc, 2015, 29(2): 398-404. DOI: 10.1007/s00464-014-3682-8.
|
[7] |
陈肖, 张红.肝移植围手术期预防感染的护理对策研究[J].河北医学, 2014, 21(5): 846-849. DOI: 10.3969 /j.issn.1006-6233.2015.05.050.Chen X, Zhang H. Nursing strategies for perioperative prophylaxis of infection in liver transplantation [J]. Hebei Med, 2014, 21(5): 846-849. 10.3969 /j.issn.1006-6233.2015.05.050. doi: 10.3969/j.issn.1006-6233.2015.05.050
|
[8] |
刘建明, 杨永洁, 刘大钺, 等.肝移植术后医院感染流行特征分析[J].中华医院感染学杂志, 2011, 2l (19): 4022-4024. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY201119030.htmLiu JM, Yang YJ, Liu DY, et al. Epidemiological analysis of nosocomial infections after liver transplantation [J]. Chin J Nosocomiol, 2011, 2l (19): 4022-4024. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY201119030.htm
|
[9] |
Fernández-Ruiz M, Silva JT, López-Medrano F, et al. Post-transplant monitoring of NK cell counts as a simple approach to predict the occurrence of opportunistic infection in liver transplant recipients [J]. Transpl Infect Dis, 2016, 18(4): 552-565. DOI: 10.1111/tid.12564.
|
[10] |
Ohira M, Ishiyama K, Tanaka Y, et al. Adoptive immunotherapy with liver allograft-derived lymphocytes induce anti-HCV activity after liver transplantation in humans and humanized mice [J]. J Clin Invest, 2009, 119(11): 3226-3235. DOI: 10.1172/JCI38374.
|
[11] |
Cheent K, Khakoo SI. Natural killer cells and hepatitis C: action and reaction [J]. Gut, 2011, 60(2): 268-278. DOI: 10.1136/gut.2010.212555.
|
[12] |
Ohira M, Nishida S, Matsuura T, et al. Comparative analysis of T-cell depletion method for clinical immunotherapy-anti-hepatitis c effects of natural killer cells via interferon-γ production [J]. Transplant Proc, 2013, 45(5): 2045-2050. DOI: 10.1016/j.transproceed.2013.01.046.
|
[13] |
Chen H, Li F, Zhan Y, et al. Circulating cytokine portraits can differentiate between allograft rejection and pulmonary infection in cardiac transplant rats [J]. Interact Cardiovasc Thorac Surg, 2016, 23(1): 118-124. DOI: 10.1093/icvts/ivw051.
|
[14] |
Howell J, Sawhney R, Testro A, et al. Cyclosporine and tacrolimus have inhibitory effects on toll-like receptor signaling after liver transplantation [J]. Liver Transpl, 2013, 19(10): 1099-1107. DOI: 10.1002/lt.23712.
|
[15] |
Ishiyama K, Ohdan H, Ohira M, et al. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans [J]. Hepatology, 2006, 43(2): 362-372. doi: 10.1002/(ISSN)1527-3350
|
[16] |
Sganga G, Spanu T, Bianco G, et al. Bacterial bloodstream infections in liver transplantation: etiologic agents and antimicrobial susceptibility profiles [J]. Transplant Proc, 2012, 44(7): 1973-1976. DOI: 10.1016/j. transproceed.2012.06.055.
|
[17] |
Bodro M, Sabé N, Tubau F, et al. Extensively drug-resistant Pseudomonas aeruginosa bacteremia in solid organ transplant recipients [J]. Transplantation, 2015, 99(3): 616-622. DOI: 10.1097/TP.0000000000000366.
|
[18] |
Sato A, Kaido T, Iida T, et al. Bundled strategies against infection after liver transplantation: lessons from multidrug-resistant pseudomonas aeruginosa [J]. Liver Transpl, 2016, 22(4): 436-445. DOI: 10.1002/lt.24407.
|
[19] |
Davidson S, Maini MK, Wack A. Disease-promoting effects of type Ⅰ interferons in viral, bacterial, and coinfections [J]. Interferon Cytokine Res, 2015, 35(4): 252-264. DOI: 10.1089/jir.2014.0227.
|
[20] |
Clifford V, He Y, Zufferey C, et al. Interferon gamma release assays for monitoring the response to treatment for tuberculosis: a systematic review [J]. Tuberculosis, 2015, 95 (6): 639-650. DOI: 10.1016/j.tube. 2015.07.002.
|
[21] |
Morton B, Pennington SH, Gordon SB. Immunomodulatory adjuvant therapy in severe community-acquired pneumonia [J]. Expert Rev Respir Med, 2014, 8(5): 587-596. DOI: 10.1586/17476348. 2014.927736.
|
[22] |
Davis CT, Rizzieri D. Immunotherapeutic applications of NK cells [J]. Pharmaceuticals, 2015, 8(2): 250-256. DOI: 10.3390/ph8020250.
|
[23] |
Adib-Conquy M, Scott-Algara D, Cavaillon JM, et al. TLR-mediated activation of NK cells and their role in bacterial/viral immune responses in mammals [J]. Immunol Cell Biol, 2014, 92(3): 256-262. DOI: 10.1038/icb.2013.99.
|
[24] |
Patidar M, Yadav N, Dalai SK. Interleukin 15: a key cytokine for immunotherapy [J]. Cytokine Growth Factor Rev, 2016, 31: 49-59. DOI: 10.1016/j.cytogfr.2016.06.001.
|
[25] |
Marçais A, Cherfils-Vicini J, Viant C, et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells [J]. Nat Immunol, 2014, 15(8): 749-757. DOI: 10.1038/ni.2936.
|
[26] |
Hamon MA, Quintin J. Innate immune memory in mammals [J]. Semin Immunol, 2016, 28(4): 351-358. DOI: 10.1016/j.smim.2016.05.003.
|